Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Second cohort data from phase I/II study of NOX-A12 in glioblastoma multiforme

June 1, 2021

Jiangsu Simcere Pharmaceutical identifies new PRMT5 inhibitors

June 1, 2021

Nerviano Medical Sciences patents IDH inhibitors

June 1, 2021

Nanjing Ruijie Pharma divulges ACC inhibitors

June 1, 2021

AbbVie initiates first-in-human study of ABBV-623 and ABBV-992

June 1, 2021

Bacteriophage delivery of TNF-alpha gene therapy suppresses chondrosarcoma tumors in vivo

June 1, 2021

Disulfiram/copper gluconate studied in phase I for treatment-refractory multiple myeloma

May 31, 2021

RNF6 and SF3B2 are novel therapeutic targets in colorectal cancer

May 31, 2021

BPRCX-807 demonstrates promising activity in models of HCC

May 31, 2021

Nanjing Sanhome Pharmaceutical synthesizes PTPN11 inhibitors

May 31, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...